Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB Number: 3235 Estimated average burden 3235-0287 0.5 hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person * STEER RANDOLPH C				2. Issuer Name and Ticker or Trading Symbol							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O BIOCRYST PHARMACEUTICALS, INC, 2190 PKWY LAKE DRIVE				TECHNE CORP /MN/ [TECH] 3. Date of Earliest Transaction (Month/Day/Year) 10/25/2007							-	X_ Director 10% Owner Officer (give title below) Other (specify below)				w)
(Street) BIRMINGHAM, AL 35244			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person						
(Cit	y)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Own					eficially Own	ned						
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)	2A. Deer Execution any (Month/I	n Dat	te, if		: 8)	(A) (Ins	Securities Acquer or Disposed of Str. 3, 4 and 5) (A) or (D)	of (D) O		wing Report s)]] (Ownership Form:	Beneficial Ownership
Reminder:	Report on a	separate line for eac	Table II - l	Derivativ	e Sec	urities	s Acq	Perso conta form	ons line dis pos	who respond in this for plays a current of, or Benevertible secur	m are n ently va	ot require lid OMB o	d to respo	nd unless tl		474 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	if Transaction of Code Derivr) (Instr. 8) Secu Acqu (A) c Disp of (L (Instr. 8))		5. Num of Deriva Securi Acquii (A) or Dispos of (D)	urities uired or oosed O) r. 3, 4,		n Date Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownersh Form of Derivativ Security: Direct (D or Indirec	(Instr. 4)
				Code	V	(A)	(D)	Date Exercisab		Expiration Date	Title	Amoun or Numbe of Shares				
Director Stock Option	\$ 66.59	10/25/2007		A	:	5,000		10/25/20	07	10/24/2017	Comm Stock	15 000	\$ 0	5,000	D	
Director Stock Option	\$ 56.17							10/26/20	06	10/25/2016	Comm	1.5 000		5,000	D	
Director Stock Option	\$ 54.68							10/27/20	005	10/26/2015	Comm Stocl	15000		5,000	D	
Repoi	rting O	wners		R	elatio	onship	s									

Reporting Owner Name / Madress	Director	10% Owner	Officer	Other
STEER RANDOLPH C C/O BIOCRYST PHARMACEUTICALS, INC 2190 PKWY LAKE DRIVE BIRMINGHAM, AL 35244	X			

Signatures

Randolph C. Steer	10/25/2007
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.	